Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Food Ingredients Chin... Food Ingredients China
Not Confirmed
Not Confirmed
17-19 March, 2026
RNA Leaders EuropeRNA Leaders Europe
Not Confirmed
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Not Confirmed
Not Confirmed
17-19 March, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Food Ingredients Chin... Food Ingredients China
Industry Trade Show
Not Confirmed
17-19 March, 2026
RNA Leaders EuropeRNA Leaders Europe
Industry Trade Show
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Industry Trade Show
Not Confirmed
17-19 March, 2026
Digital content

10 Mar 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/soligenix-announces-sgx945-receives-promising-innovative-medicine-designation-from-the-uk-medicines-and-healthcare-products-regulatory-agency-302709102.html

26 Feb 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/soligenix-receives-positive-opinion-from-the-european-medicines-agency-on-the-request-for-orphan-drug-designation-for-sgx945-for-the-treatment-of-behcets-disease-302698032.html

12 Feb 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/soligenix-details-recent-progress-and-upcoming-milestones-302686179.html

18 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/positive-clinical-results-from-phase-2-trial-of-sgx945-for-the-treatment-of-behcets-disease-published-in-rheumatology-oxford-302645452.html

17 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/soligenix-announces-top-line-results-of-the-phase-2a-study-of-sgx302-synthetic-hypericin-in-patients-with-mild-to-moderate-psoriasis-302644314.html

05 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/05/3200703/0/en/Soligenix-Inc-NASDAQ-SNGX-Advancing-Rare-Disease-Therapies-Positioned-at-Pivotal-Crossroad.html
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE